[go: up one dir, main page]

IN2012DN02968A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02968A
IN2012DN02968A IN2968DEN2012A IN2012DN02968A IN 2012DN02968 A IN2012DN02968 A IN 2012DN02968A IN 2968DEN2012 A IN2968DEN2012 A IN 2968DEN2012A IN 2012DN02968 A IN2012DN02968 A IN 2012DN02968A
Authority
IN
India
Prior art keywords
present
relates
heterocyclic
schizophrenia
solvate
Prior art date
Application number
Inventor
Paul David Ratcliffe
Thomas Russell Clarkson
Fiona Jeremiah
John Kinnaird Ferguson Maclean
Original Assignee
Msd Oss Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Oss Bv filed Critical Msd Oss Bv
Publication of IN2012DN02968A publication Critical patent/IN2012DN02968A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by nicotinic acetylcholine receptors, such as schizophrenia and Alzheimer's disease.
IN2968DEN2012 2009-10-13 2010-10-11 IN2012DN02968A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25110109P 2009-10-13 2009-10-13
EP09172872 2009-10-13
PCT/EP2010/065160 WO2011045258A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Publications (1)

Publication Number Publication Date
IN2012DN02968A true IN2012DN02968A (en) 2015-07-31

Family

ID=42040651

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2968DEN2012 IN2012DN02968A (en) 2009-10-13 2010-10-11

Country Status (12)

Country Link
US (1) US8841289B2 (en)
EP (1) EP2488520B1 (en)
JP (1) JP2013507417A (en)
KR (1) KR20120100913A (en)
CN (1) CN102666540A (en)
AU (1) AU2010305825A1 (en)
BR (1) BR112012008518A2 (en)
CA (1) CA2776835A1 (en)
IN (1) IN2012DN02968A (en)
MX (1) MX2012004289A (en)
RU (1) RU2012119488A (en)
WO (1) WO2011045258A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014001265A2 (en) 2011-07-29 2017-02-21 Taisho Pharmaceutical Co Ltd amidine compound or its salt
EP2822656B1 (en) 2012-03-07 2016-10-19 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
AU2013264943B2 (en) * 2012-05-22 2018-02-01 King Abdullah University Of Science And Technology Combination comprising parthenolide for use in the treatment of Alzheimer's Disease and other neurodegenerative disorders
AU2014320149A1 (en) 2013-09-11 2016-04-07 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
CA2971413A1 (en) 2014-12-16 2016-06-23 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
TWI698436B (en) 2014-12-30 2020-07-11 美商佛瑪治療公司 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
JP2018504431A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Thienopyrimidinone as a ubiquitin-specific protease 7 inhibitor
HK1248220A1 (en) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
HK1248221A1 (en) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
CN106146410B (en) * 2015-04-03 2018-10-12 中南大学 6- amino -4 (3H)-Quinazol derivative and its preparation method and use
CN106279211B (en) * 2015-06-03 2020-09-15 北京大学 A kind of thiazolopyrimidone compound and its preparation method and application
MX2017016231A (en) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors.
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH Geminal substituted aminobenzisoxazole compounds as agonists of 7-nicotinic acetylcholine receptors
PT3386591T (en) 2015-12-09 2020-10-01 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and uses thereof
ES2950348T3 (en) 2015-12-09 2023-10-09 Novartis Ag Thienopyrimidinone NMDA receptor modulators and uses thereof
WO2018119374A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics Nmda receptor modulators and uses thereof
EA202190116A1 (en) 2018-06-27 2021-08-30 Реборна Биосайенсиз, Инк. AGENT FOR PREVENTION OR TREATMENT OF SPINAL MUSCLE ATROPHY
HU231414B1 (en) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Thiadiazine derivatives
CN112566906B (en) 2018-07-26 2024-11-12 多曼治疗学公司 Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4
IL280474B2 (en) 2018-08-03 2023-09-01 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and uses thereof
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
EP4126847A1 (en) 2020-03-30 2023-02-08 ENYO Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN112898290B (en) * 2021-01-29 2022-08-05 中南大学 Isoxazole formamido-4 (3H) -quinazolinone derivative and synthesis method and application thereof
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2025176185A1 (en) * 2024-02-23 2025-08-28 海思科医药集团股份有限公司 Preparation method for braf inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (en) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
JP2005504730A (en) * 2001-04-20 2005-02-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド Compositions useful as GSK-3 inhibitors
WO2003062235A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
PT1910333E (en) * 2005-07-26 2013-08-01 Sanofi Sa Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
ATE523500T1 (en) * 2006-09-11 2011-09-15 Organon Nv QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES
WO2008077555A2 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
JP2010229035A (en) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd Pyridopyrimidin-4-one derivatives
WO2009062988A1 (en) * 2007-11-14 2009-05-22 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use
EP2249455A1 (en) 2008-02-29 2010-11-10 Techno Core International Co., Ltd. Charging device and quality judging device of pack cell

Also Published As

Publication number Publication date
US8841289B2 (en) 2014-09-23
JP2013507417A (en) 2013-03-04
EP2488520B1 (en) 2015-09-02
CN102666540A (en) 2012-09-12
EP2488520A1 (en) 2012-08-22
US20120208796A1 (en) 2012-08-16
KR20120100913A (en) 2012-09-12
RU2012119488A (en) 2013-11-20
WO2011045258A1 (en) 2011-04-21
BR112012008518A2 (en) 2016-04-05
AU2010305825A1 (en) 2012-04-19
MX2012004289A (en) 2012-06-12
CA2776835A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
IN2012DN02968A (en)
WO2011051490A3 (en) Heterocyclic derivatives
IN2014DN03206A (en)
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
MX2009000531A (en) Fused heterocyclic derivatives and methods of use.
MX2010007683A (en) Fused heterocyclic derivatives and methods of use.
MX2014000341A (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
WO2009050242A3 (en) Heterocycle-substituted piperazino-dihydrothienopyrimidines
MX2009006543A (en) Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer.
MX2014015158A (en) Pyridinone and pyridazinone derivatives.
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
MX2009010407A (en) Fluorinated derivatives of deferiprone.
WO2008023258A8 (en) Piperidine derivatives
MX2010002900A (en) Tricyclic heterocyclic derivatives.
MX2010004686A (en) Heterocyclic derivatives.
PH12015500012A1 (en) Benzodioxole derivative and preparation method and use thereof
MX2010012189A (en) Quinuclidine derivatives as muscarinic m3 receptor antagonists.
MX2009012518A (en) 4,4-disubstituted piperidine derivatives.
MX2009007038A (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders.
MX2010004620A (en) Benzomorpholine derivatives and methods of use.
MX2009005242A (en) 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof.
MX2009006757A (en) 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands.
PH12016500197B1 (en) Biphenyl derivative and method for preparing same
WO2013043744A3 (en) Tricyclic compounds useful as neurogenic and neuroprotective agents